The mammary ductal tree is comprised of stem cells, progenitor cells, and more differentiated epithelial and myoepithelial cells. Stem and progenitor cells are increasingly thought to be the primary targets of tumorigenesis, and indeed mammary tumors initiated by oncogenes such as Wnt-1 contain a mix of cell types implying that they arose from multipotent progenitors. However, tumors initiated by other important oncogenes such as ErbB2 usually do not contain mixed cell types, suggesting that they might originate from transformation of more differentiated cells. Furthermore, these tumors differ in their estrogen receptor status, so that the dependence on estrogen for tumor development may also differ. To test rigorously whether different oncogenes induce tumors preferentially from different mammary cell differentiation states, we use the avian retrovirus (RCAS) somatic gene transfer technique to target cells transgenically engingeered to express the gene encoding the RCAS receptor TVA - we were the first to adapt this technique to the mammary gland, and have already developed several mouse strains expressing tva from different mammary cell types and differentiation stages and begun to study tumor formation induced in these strains by several oncogenes carried by RCAS. Our preliminary data strongly suggest the hypothesis that different oncogenes do indeed prefer to induce tumors from different cell types and differentiation states in the mammary gland. Because understanding different paths to breast cancer evolution at both molecular and cellular levels could be critical for devising early prevention strategies, we propose here to use our uniquely suited models to: (1) determine whether differentiated mammary cells are more susceptible than progenitor cells (defined by new, more selective promoters) to tumor induction by ErbB2, and whether this susceptibility is due to the failure of the more differentiated cells to erect an oncogenic barrier involving the DNA damage response;(2) investigate whether mammary progenitor cells are more susceptible to induction of early lesions and tumors by Wnt-1, and what molecular network in the progenitor cells is preferentially activated by Wnt signaling to accelerate tumor development;and (3) determine how estrogen (or estrogen deprivation) affects tumor evolution induced by ErbB2 vs. Wnt in differentiated vs. progenitor cells, and which molecular mechanisms are involved in this estrogen dependence.

Public Health Relevance

The breast ducts in which breast cancer arises are lined with at least two kinds of mature epithelial cells, but also contain small numbers of stem cells that can divide to renew themselves and can also generate progenitor cells and new mature cells. Many people have begun to think that cancer arises from an oncogenic mutation in the stem cells, but our evidence suggests that while this is true for some important oncogenes like Wnt, others like ErbB2 (Her2) may preferentially initiate tumors in mature cells. If we knew why different oncogenes work best in different cell types, and why some but maybe not others are dependent on estrogen, we could more accurately define cell-type-specific treatment targets and devise better early prevention strategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA124820-03
Application #
8208111
Study Section
Molecular Oncogenesis Study Section (MONC)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2010-04-01
Project End
2015-01-31
Budget Start
2012-02-01
Budget End
2013-01-31
Support Year
3
Fiscal Year
2012
Total Cost
$308,957
Indirect Cost
$107,682
Name
Baylor College of Medicine
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Holloway, Kimberly R; Sinha, Vidya C; Bu, Wen et al. (2016) Targeting Oncogenes into a Defined Subset of Mammary Cells Demonstrates That the Initiating Oncogenic Mutation Defines the Resulting Tumor Phenotype. Int J Biol Sci 12:381-8
Choi, Soyoung; Chen, Zhengming; Tang, Laura H et al. (2016) Bcl-xL promotes metastasis independent of its anti-apoptotic activity. Nat Commun 7:10384
Holloway, Kimberly R; Sinha, Vidya C; Toneff, Michael J et al. (2015) Krt6a-positive mammary epithelial progenitors are not at increased vulnerability to tumorigenesis initiated by ErbB2. PLoS One 10:e0117239
Shi, Aiping; Dong, Jie; Hilsenbeck, Susan et al. (2015) The Status of STAT3 and STAT5 in Human Breast Atypical Ductal Hyperplasia. PLoS One 10:e0132214
Sinha, Vidya C; Qin, Lan; Li, Yi (2015) A p53/ARF-dependent anticancer barrier activates senescence and blocks tumorigenesis without impacting apoptosis. Mol Cancer Res 13:231-8
Zheng, Ze-Yi; Tian, Lin; Bu, Wen et al. (2015) Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. Cell Rep 12:511-24
Haricharan, S; Hein, S M; Dong, J et al. (2014) Contribution of an alveolar cell of origin to the high-grade malignant phenotype of pregnancy-associated breast cancer. Oncogene 33:5729-39
Hatcher, Rashieda J; Dong, Jie; Liu, Shuang et al. (2014) Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis. Proc Natl Acad Sci U S A 111:1008-13
Qin, Li; Wu, Ye-Lin; Toneff, Michael J et al. (2014) NCOA1 Directly Targets M-CSF1 Expression to Promote Breast Cancer Metastasis. Cancer Res 74:3477-88
Haricharan, Svasti; Dong, Jie; Hein, Sarah et al. (2013) Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. Elife 2:e00996

Showing the most recent 10 out of 22 publications